Saturday 17 October 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXS Healthcare Biotechnology
Pyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024. In the quarter to June 2026, EPS fell 33.3% and free cash flow fell 5.46%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.68
0.12
−6.67%
Follow PYXS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
— | — | 0.00 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (6.85) | — | |
P/B ratio |
— | — | 1.34 | — | |
Price to Tangible BV |
— | — | 1.40 | — | |
EV/Sales |
— | — | 0.00 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (0.05) | — | |
EV/FCF |
— | — | (0.05) | — | |
Quick Ratio |
1.25 | 2.57 | 3.23 | 4.01 | |
Current Ratio |
1.34 | 2.76 | 3.41 | 4.29 | |
Net Debt/EBITDA |
1.33 | 1.76 | 4.33 | 3.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 1.12 | 0.58 | 0.60 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 1.80 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 196.69% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 47.42% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 18.86% | 0.00% | |
Graham Net Nets |
— | — | 0.48 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (112.17%) | — | |
Free Cash Flow Yield |
— | — | (88.87%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.18 | 0.00 | |
Operating CF per Share |
(0.28) | (0.41) | (0.17) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.41) | (0.17) | (0.21) | |
Cash per Share |
0.54 | 0.67 | 1.10 | 1.24 | |
Shareholders Equity per Share |
0.18 | 0.49 | 0.86 | 1.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.18 | 0.49 | 0.86 | 1.10 | |
Free Cash Flow |
(18.21) | (26.00) | (10.43) | (13.29) | |
Working Capital |
9.26 | 29.04 | 50.97 | 63.69 | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
(6.75) | 12.54 | 33.99 | 46.25 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
6.34 | 3.92 | 7.87 | 7.31 | |
Average Assets |
89.07 | 100.08 | 124.35 | 150.46 | |
Average Common Equity |
49.54 | 67.19 | 87.08 | 111.23 |
Columns are period end dates